Relaxin therapy reverses large artery remodelling and stiffening in aged and hypertensive models

松弛素疗法可逆转老年和高血压模型中的大动脉重塑和硬化

• 批准号: nhmrc : 1004235
• 负责人: A/Pr Chrishan Samuel
• 金额: $ 29.67万
• 依托单位: Baker IDI Heart and Diabetes Institute
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2011
• 资助国家: 澳大利亚
• 起止时间: 2011-01-01 至 2014-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/relaxin-therapy-reverses-hypertensive-models/109019
• 关键词: Relaxin; therapy; reverses; large; artery

Hypertension and/or ageing result in morphological changes in large arteries with increased stiffness, which impacts negatively to cardiac function and increases the risk of cardiovascular disease. Currently there is no drug that can specifically and rapidly reverse the changes in large arteries. We will study a peptide hormone relaxin as a promising candidate drug in this setting. Our recent study strongly indicate the effectiveness of relaxin in softening stiffened large arteries.

高血压和/或衰老会导致大动脉形态变化，硬度增加，对心脏功能产生负面影响，并增加患心血管疾病的风险。目前还没有药物可以特异性地快速逆转大动脉的变化。我们将研究一种肽激素松弛素作为一种有前途的候选药物在这种情况下。我们最近的研究有力地表明松弛素在软化硬化的大动脉中的有效性。